Brief: Poxel Initiates Phase 1B MAD Trial For Nash Drug Candidate

Poxel SA

17/09/2019 07:07

Sept 17 (Reuters) - Poxel SA  POXEL.PA :
    * POXEL INITIATES PHASE 1B MULTIPLE ASCENDING DOSE (MAD) TRIAL FOR NASH DRUG
CANDIDATE, PXL065
    * PHASE 1B MAD TRIAL IS DESIGNED TO EVALUATE SAFETY, TOLERABILITY AND
PHARMACOKINETICS (PK) AND SUPPORT DOSE SELECTION FOR A PIVOTAL STUDY; TOPLINE
RESULTS EXPECTED IN Q4 2019
    * RESULTS FROM PHASE 1A SINGLE ASCENDING DOSE (SAD) STUDY OF PXL065 TO BE
PRESENTED AT AMERICAN ASSOCIATION FOR STUDY OF LIVER DISEASES (AASLD) ANNUAL
MEETING, NOVEMBER 8-12, 2019 IN BOSTON, MA
    * POXEL WILL MEET WITH U.S. FOOD AND DRUG ADMINISTRATION (FDA) IN EARLY Q4
2019 TO
DISCUSS REGISTRATION PROGRAM AND 505(B)(2) REGULATORY PATHWAY

Source text for Eikon:  ID:nBw2W0B1sa 
Further company coverage:  POXEL.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))